June 26th 2025
The next-generation monoclonal antibody could potentially be used to prevent and treat active COVID-19 infections, according to its developer, providing a non-vaccine option.
March 17th 2025
Under the agreement, Shilpa will undertake development and commercial supply for a novel checkpoint inhibitor for immuno-oncology indications.
March 4th 2025
EMA’s CHMP recommended conditional marketing authorization for linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
January 10th 2025
Bora said it will be involved in stages ranging from chemistry, manufacturing, and controls strategy through to clinical development.
November 21st 2024
The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.
Lonza’s Synaffix and BigHat Biosciences Team Up on Machine Learning-Designed ADCs
Lonza’s Synnafix has licensed its ADC technology to BigHat Biosciences, which will combine it with its ML design platform to generate newly designed ADCs.
Glycosylation Analysis for Multispecifics
The best strategy is to use a combination of complementary methods.
Syngene Launches Rapid Protein Synthesis Platform
Syngene has launched a new protein production platform that offers faster production with lower risk.
Lonza Set to Manufacture Acumen Pharmaceuticals’ mAb for Alzheimer’s Disease
Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.
ProBioGen and Mapp Biopharmaceutical Partner to Develop Antibody Against Marburg Virus Disease
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 2
The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.
Samsung Biologics Partners with LegoChem Biosciences on ADCs
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
Purolite and Repligen Launch New Affinity Resin
Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.
Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 1
The authors present a methodology to assess the contribution of individual filters to overall capacity of the direct filtration train, and elucidate how capacity is affected by characteristics of the cell culture broth and process parameters, including for enhanced upstream processes such as those incorporating high cell density perfusion.
Abzena Launches New Cell Line Development Platforms
Abzena has launched its AbZelect platforms, designed for improving cell line development.
The Pros and Cons of Adherent Versus Suspension Cell Culture
Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.
Lonza Launches New Cell Line for Higher Potency Antibody Development
Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.
Aragen to Establish $30 Million Biomanufacturing Facility in India
As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.
Optimization of Linker Chemistries for Antibody-Drug Conjugates
There is no such thing as a perfect linker.
Remembering Raw Material Basics for mAb Production
Re-evaluating the basics of mAb production may be beneficial for the biopharma industry as a whole.
Image Analysis Algorithm for Therapeutic mAb Aggregate Analysis
Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.
Pushing Forward in Next-Gen Antibody Development
Exploring new fields can bring novel antibody candidates to the pipeline.
Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
Small-Scale Syringe and Vial-Filling Capability for Development of Robust Filling Processes, Smooth Tech Transfers, and to Resolve Manufacturing Issues: Summary of Key Learnings
Use of a small-scale filler can result in increased filling efficiency.
Pushing the Barriers in Next-Gen Antibody Development
New fields are being explored to bring novel antibody candidates to the pipeline.
Pulling Out All the Stops in mAb Manufacturing
Compliance with GMP standards remains an integral focus in bulk mAb manufacturing.
Purification of Antibodies Using Novel Convecdiff Membranes Part 2: Robust Performance at Comparable Product Quality
In part 2 of this article, results from the testing of a next generation convecdiff membrane are discussed.
Improving the Fate of ADCs
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
Streamlining Bulk mAb Manufacturing
The projected growth in the biosimilars market will require increased bulk mAb manufacturing.
Approaches to Scaling Up Chromatography Processes
Scaling up chromatography resins requires a thorough understanding of their intended use.
Continuous Processing for Viral Vectors
Manufacturers are taking the first steps toward process intensification.
MilliporeSigma’s ZooMAb Antibodies Earn ACT Label from My Green Lab
MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.
Large-Scale Single-Use Bioreactors Can Maximize Long-Term Scale Up
The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.
What’s New in Downstream Processing?
The past year of downstream processing has brought innovations in pH sensitive antibody purification, single-use fermentation separators, and more.
AstraZeneca’s Antibody Combination Authorized for Use in Great Britain for Prevention of COVID-19
AstraZeneca’s antibody combination has been authorized for use in Great Britain to prevent COVID-19 in high-risk populations and people for whom vaccination may not be effective.